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This year’s Nobel Prize in Physiology or Medicine rewards the discoverers of two viruses that 
cause major afflictions of humankind. Identifying human papilloma virus (HPV) and human immu-
nodeficiency virus (HIV) might now appear to have been simple, but the way forward was far from 
obvious at the time.Virologists, oncologists, and infectious 
disease physicians are delighted that 
this year’s Nobel Prize in Physiology or 
Medicine recognizes the elucidation 
of the causes of cervical cancer and 
acquired immune deficiency syndrome 
(AIDS). One half of the Prize has been 
awarded to Harald zur Hausen of the 
German Center for Cancer Research in 
Heidelberg for his discovery (while at 
the University of Freiburg) of “human 
papilloma viruses causing cervical can-
cer.” The other half of the Prize is shared 
between Françoise Barré-Sinoussi and 
Luc Montagnier for their discovery of 
“human immunodeficiency virus (HIV)” 
at the Pasteur Institute in Paris. The key 
papers were both published 25 years 
ago (Dürst et al., 1983; Barré-Sinoussi et 
al., 1983).
Some might question why the Nobel 
Committee coupled HIV with HPV, when 
no prize can be shared by more than 
three people. But virus discovery com-
petes with all other areas of medicine, so 
it is fitting to recognize two of the most 
important viral pathogens together. 
HIV-1 and human papilloma viruses of 
the uterine cervix (HPV-16 and HPV-18) 
cause immense morbidity and mortality; 
both are sexually transmitted and both 
establish life-long, persistent infections. 
HPV represents a new discovery of an 
ancient infection whereas HIV-1 is new 
to humans, the latest data (Worobey et 
al., 2008) refining Bette Korber’s previ-
ous estimate of an origin of the pan-
demic strain 75–100 years ago. The dis-
covery of HPV eventually led to excellent 
prophylactic vaccines, whereas the dis-
covery of HIV-1 led to effective antiviral 
drugs but, alas, no safe and efficacious 
vaccine is yet in sight.
Cervical carcinoma has long been 
thought to be sexually transmissible. 
In 1842, one sagacious gentleman of 
Verona, Domenico Rigoni-Stern, noted 
that it occurred more frequently among 
sex workers than nuns. By the 1970s 
when zur Hausen began his investiga-
tions, the chief suspect was herpes 
simplex virus type II (HSV-II). However, 
although HSV-II is a sexually transmitted 
infection, longitudinal studies by Vladi-
mir Vonka and others did not indicate a 
strong link between this virus and cervi-
cal cancer.
Harald zur Hausen came from a her-
pes virus background, having studied 
Epstein-Barr virus (EBV) with Gertrude 
and Werner Henle in Philadelphia. He was 
the first scientist to develop molecular 
probes for human viruses, demonstrat-
ing in 1970 the presence of EBV DNA in 
Burkitt’s lymphoma and nasopharyngeal 
carcinoma. After his return to Germany 
in 1974, zur Hausen used DNA hybrid-
ization and restriction enzyme polymor-
phisms to initiate the numerical sys-
tem of HPV typing and to classify HPV 
strains in plantar and flat warts (HPV-1 to 
-4). In 1972, an association of papilloma 
viruses with skin cancer in epidermodys-
plasia verruciformis had been proposed 
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1978 she and Gerard Orth at the Pasteur 
Institute discovered HPV-5 in this skin 
cancer using zur Hausen’s methods.
zur Hausen and his young colleagues 
Herbert Pfister, Lutz Gissman, and Mat-
thias Dürst characterized new strains 
of HPV. They discovered HPV-6 in con-
dyloma acuminata (genital warts) and 
also identified a second virus in epider-
modysplasia verruciformis, HPV-8. Hav-
ing cloned these genomes, they used an 
HPV-6 probe to detect DNA of another 
strain (HPV-11) in laryngeal tumors, geni-
tal condylomas, and a small proportion 
of cervical cancer specimens. Then they 
exploited low stringency hybridization 
to HPV-11 to identify a new genome, 
HPV-16, present in 11 out of 18 cervi-
cal carcinomas (Dürst et al., 1983). The 
subsequent identification of HPV-18 
increased this association and revealed 
the persistence of HPV-18 in cervical 
tumor cell lines such as HeLa (Boshart et 
al., 1984). Further oncogenic strains such 
as HPV-31 and HPV-45 were detected, 
and today >99.7% of cervical cancers 
worldwide are known to carry one or 
more strains of HPV.
Another classic contribution by zur 
Hausen’s group followed from their 
observation that HPV-18 frequently 
becomes integrated into host DNA 
in tumors (Boshart et al., 1984). They 
noted that in each case the open read-
ing frames for E6 and E7 are preserved 
and expressed (Schwarz et al., 1985). 
This study pinpointed the importance of 
these genes in carcinogenesis, work that 
has been greatly extended by Peter How-
ley and others in the United States, who 
showed that the oncogenic HPV strains 
had a high-affinity interaction of viral pro-ecember 12, 2008 ©2008 Elsevier Inc. 983
teins E6 and E7, respectively, 
with the p53 and Rb tumor 
suppressor proteins.
The most important public 
health outcome of zur Haus-
en’s discovery has been the 
recent development of vac-
cines by GlaxoSmithKline 
and by Merck that prevent 
infection by the most frequent 
oncogenic HPV strains (Schil-
ler et al., 2008). The vaccines 
are highly effective against 
HPV-16 and -18 and thus can 
prevent ~70% of cervical HPV 
infections. They are based on 
the self-assembly of the viral capsid pro-
tein L1 into virus-like particles pioneered 
by Doug Lowy and John Schiller at NIH, 
and by Jian Zhou and Ian Frazer in Bris-
bane (Figure 1A).
zur Hausen’s success in identifying 
noncultivatable, new human papilloma 
viruses by DNA cloning led to the identi-
fication by molecular techniques of other 
human viral pathogens, such as hepati-
tis C virus in 1989 and Kaposi’s sarcoma 
herpes virus (KSHV) in 1994. Unknown 
and unexpected viruses, such as the 
SARS coronavirus outbreak in 2003, 
have been rapidly characterized thanks 
to modern cloning and sequencing tech-
nology. The most recent virus discovery 
is a new polyomavirus associated with 
Merkel cell skin cancer in AIDS patients, 
by Yuan Chang and Pat Moore who also 
discovered KSHV (Feng et al., 2008).
Human Immunodeficiency Viruses
When AIDS was first reported in a handful 
of homosexual men in the United States 
in June 1981, it was not initially clear 
whether an infection triggered the loss 
of CD4+ T cells that resulted in immuno-
deficiency. Other possible causes were 
proposed, such as recreational drugs or 
exposure to different human leukocyte 
antigens from multiple sexual partners. 
With the observation of AIDS in injecting 
drug users, and in recipients of blood 
and blood products, it became evident 
that a transmissible agent was to blame. 
In fact, thanks to superb epidemiological 
investigations at the Centers for Disease 
Control and Prevention in the United 
States, by early 1983 we already knew 
much about the risk factors associated 
with AIDS; all that was missing was the 
infective agent itself. Various microbes 
were mooted, including DNA viruses, 
RNA viruses, and a fungus secreting 
an immunosuppressive molecule like 
cyclosporin.
It was Robert C. Gallo at NIH who 
first championed the notion that a ret-
rovirus might be the cause of AIDS. His 
group had recently discovered the first 
two human retroviruses (HTLV-I and -II). 
Although I studied these retroviruses, 
kindly provided by Gallo, I did not con-
sider a retrovirus to be a strong candi-
date. I thought that a fragile, enveloped 
virus would not survive the preparation of 
clotting factors used to treat hemophilia 
and favored a nonenveloped virus such 
as a parvovirus—how wrong I was! Then, 
in the same issue of Science in which 
Barré-Sinoussi et al. (1983) reported 
“lymphadenopathy virus” (LAV), Gallo 
and Max Essex published papers indi-
cating that approximately 10% of AIDS 
and lymphadenopathy patients were 
infected with HTLV-I. This was indeed 
the case, but not the cause; it was analo-
gous to finding HSV-II in a proportion of 
women with cervical cancer.
The laboratory work at the Pasteur 
Institute started with a lymph node 
biopsy provided to Luc Montagnier by 
Willy Rozenbaum, taken from a homo-
sexual man with persistent lymphade-
nopathy. Montagnier teased the tissue 
apart and stimulated the T cells to pro-
liferate in vitro. The cultures did not grow 
well but were passed on to Françoise 
Barré-Sinoussi in Jean-Claude Cher-
mann’s laboratory. At the time, she was 
the most experienced retrovirologist at 
the Pasteur Institute, having worked on 
murine leukemia virus.
One of Louis Pasteur’s 
best known aphorisms is 
that “Chance favors the pre-
pared mind.” Barré-Sinoussi 
proved to be a Pasteurienne 
par excellence. She observed 
that the lymphocytes in the 
culture were not growing but 
dying, making it exasperat-
ingly difficult to maintain the 
precious biopsy and requiring 
the addition of fresh lympho-
cytes. She realized that an 
AIDS agent that causes CD4 
T cell depletion in vivo might 
well be cytopathic in vitro. She 
found that the supernatant contained a 
filterable agent that could transfer the kill-
ing effect to T cells cultured from healthy 
donors. Moreover, the supernatant con-
tained reverse transcriptase activity (the 
hallmark of a retrovirus) and the infected 
cells were bristling with budding virus 
particles, although they did not have a 
morphology typical of oncogenic retrovi-
ruses (Barré-Sinoussi et al., 1983).
The observation of a cytopathic retro-
virus from a single patient did not make 
headlines when it was published in May 
1983 among the various claims of other 
putative AIDS agents. Confirmation that 
this new retrovirus really was the cause 
of AIDS was cemented by further inde-
pendent isolations, first by the Pasteur 
Institute (Vilmer et al., 1984), and then by 
Gallo’s group (Popovic et al., 1984) and 
by Jay Levy in San Francisco (Levy et 
al., 1984). Gallo’s work in particular con-
vinced the wider research community 
that a new retrovirus was the genuine 
culprit. Serological tests were rapidly 
developed in several laboratories that 
revealed the high prevalence of infection 
in various AIDS “risk” groups.
I should admit that I did not take the 
1983 French report seriously until 3 
months later at Cold Spring Harbor Labo-
ratory, when Luc Montagnier showed me 
Charles Dauguet’s new electron micro-
graphs of mature retrovirus particles and 
data on the new isolates derived from 
the peripheral blood of AIDS patients. 
Montagnier sent us a virus sample, but 
we could not propagate it successfully. 
Later, he suggested trying a laboratory-
adapted, more “virulent” stock of virus, 
and on February 29, 1984 Rachanee 
Cheingsong brought it from the Pasteur 
Figure 1. Viruses in the Spotlight
(A) A model of a virus-like particle of the HPV vaccine in which recombinant L1 
proteins assemble into pentamers, which in turn form particles (image cour-
tesy of Mark Feinberg, Merck & Co, Inc.). 
(B) HIV particles (artificially colored red) budding from a CD4+ T lymphocyte 
(image courtesy of David Hockley and Robin A. Weiss).984 Cell 135, December 12, 2008 ©2008 Elsevier Inc.
Institute to London. Within 2 weeks, it 
was producing enormous titers in the 
CEM T cell line, and these cells became 
the source of antigen for the Elavia and 
Wellcozyme diagnostic tests. With hind-
sight, we know that the first sample we 
received was the CCR5-tropic HIV iso-
late Bru, and the high-titer stock was the 
CXCR4-tropic isolate Lai (Wain-Hobson 
et al., 1991); Lai was also propagated 
by Mika Popovic in Gallo’s laboratory as 
HTLV-IIIB.
Each group used a different acronym 
for their viruses: LAV and IDAV (Montag-
nier), HTLV-III (Gallo), and ARV (Levy). 
In 1986, a committee chaired by Harold 
Varmus coined the name HIV (Essex and 
Gallo dissenting), which soon became 
common parlance. Thanks to pre-existing 
knowledge of retrovirus replication, anti-
retroviral therapy trials were undertaken 
in 1986 by Sam Broder and colleagues 
at the NIH of azidothymidine (Zidovu-
dine), which acts as a chain terminator 
of reverse transcription. However, owing 
to the rapid emergence of drug-resistant 
virus, treatment only became success-
ful when drug combinations were intro-
duced a decade later.
The World Is the Winner
Whereas zur Hausen’s contribution 
undoubtedly towers over HPV, there has 
been debate about HIV. Initially, the Pas-
teur Institute scientists were spoken of 
as a trio, namely Luc Montagnier, Jean-
Claude Chermann, and Françoise Barré-
Sinoussi, but given that the Nobel Com-
mittee had a maximum of two names 
to award for the discovery of HIV, the 
choice of the 5′ and 3′ authors on the 
first paper (Barré-Sinoussi et al., 1983) 
seems just. At the AIDS Vaccine Confer-
ence held in Cape Town a few days after 
the announcement of the Prize, there was 
evident satisfaction among the partici-
pants that Barré-Sinoussi’s crucial con-
tribution had at last been recognized.
The Nobel Committee’s scrupulous 
sifting of nominees is an onerous task 
and one of the more invidious decisions 
must be to define the precise field of 
each year’s award. Inevitably, those who 
champion unsuccessful nominees cry 
“if only.” If the Committee had decided 
to recognize human retroviruses, Gallo’s 
discovery of HTLV-I (Poiesz et al., 1980) 
would stand alongside Barré-Sinoussi’s and Montagnier’s discovery of HIV. The 
discovery of HTLV-I came 18 months 
before the beautiful work of Isao Miyoshi 
and Yorio Hinuma in Japan, who showed 
its causal link to adult T cell leukemia. 
On the other hand, had the Committee 
been minded to recognize the discovery 
of human oncogenic viruses, Gallo and 
Sir Anthony Epstein (who detected EBV 
in 1964) might have joined zur Hausen. 
The Committee stated that zur Hausen 
“went against current dogma and postu-
lated that HPV caused cervical cancer” 
(although Orth had proposed the same). 
Likewise, many scientists thought that 
Epstein and Gallo were wasting their 
time searching for oncogenic viruses in 
humans. Either way, Gallo had a near-
miss, which he has taken graciously.
Regarding HIV, Gallo’s insistence 
that HTLV-III was a new member of the 
same family of retroviruses as HTLV-I 
and HTLV-II confused the field through-
out 1984. In contrast, the Pasteur Insti-
tute’s team was unencumbered by this 
mindset. Following their first HIV-1 iso-
late from a patient with lymphadenopa-
thy (Barré-Sinoussi et al., 1983), they 
published on further isolates from AIDS 
patients (Vilmer et al., 1984) and noted 
their resemblance to a lentivirus (Mon-
tagnier et al., 1984) before Gallo and 
Levy reported their findings. Montag-
nier’s team was also the first to isolate 
HIV-1 from African patients (Ellrodt et 
al., 1984) and later discovered HIV-2 in 
West Africa (Clavel et al., 1986). None-
theless, it was Gallo’s four papers in May 
1984 that persuaded the world that the 
AIDS culprit really had been found. Gallo 
has continued to provide innovation and 
insight into HIV-1 and AIDS to this day.
Will there be further Nobel Prizes in 
virology? I expect so because viruses 
have provided such penetrating tools 
to understand the molecular workings 
of host cells and because viruses will 
continue to emerge as threats to human 
health. If we actually attain an effective 
HIV vaccine through some brilliant new 
discovery in immunology or virology, I 
would gladly nominate a second HIV-1 
award. However, only one Nobel Prize 
has been awarded for a viral vaccine, 
to Max Theiler in 1951 for “his discover-
ies concerning yellow fever and how to 
combat it.” To ambitious young investi-
gators, I would say: tackle the big sci-Cell 135, Dentific questions but do not chase elu-
sive prizes. One of my mentors (Peter 
Medawar, Nobel Prize 1960) pointed out 
that “science is the art of the soluble,” so 
judging when a problem is ripe for dis-
covery is also important.
From its inception, the choice of Nobel 
Laureates in Physiology or Medicine has 
been contentious. One could argue that 
the very first award in 1901 to Emil von 
Behring for diphtheria serum therapy 
should have been shared with Shiba-
saburo Kitasato because the develop-
ment of antitoxin to tetanus by Kitasato 
and Behring preceded that of diphtheria; 
yet the Nobel Committee chose diph-
theria alone, probably because it was 
the more feared disease. The 1902 Prize 
recognized Ronald Ross for demonstrat-
ing in 1898 that avian malaria can be 
transmitted by mosquitoes but astonish-
ingly (in retrospect) omitted Gianni-Bat-
tista Grassi in Italy who contemporane-
ously identified the mosquito vectors of 
human malaria. It is a sobering thought 
that among the 192 Nobel Laureates in 
Medicine, three at most are household 
names: Sir Alexander Fleming, Jim Wat-
son, and Francis Crick.
Given that the Nobel Prize for Litera-
ture overlooked James Joyce, Marcel 
Proust, Virginia Woolf, Franz Kafka, and 
Graham Greene, one might ask, “which 
virologists are most distinguished by 
omission?” My first choice would be 
Friedrich Loeffler, who discovered the 
first animal virus with Paul Frosch in 
1898 (the virus causing foot-and-mouth 
disease). Previously, Loeffler had dis-
covered the diphtheria bacterium and 
precisely enunciated the postulates that 
he ascribed to his mentor, Robert Koch. I 
wonder about Sir Christopher Andrewes, 
who identified human influenza virus in 
1933. Alick Isaacs, like Proust and Kafka, 
sadly died too soon after his and Jean 
Lindermann’s discovery of interferon in 
1957 to gain recognition. This finding of 
an innate antiviral response was also the 
first discovery of a cytokine, long before 
the interleukins. Perhaps the most nota-
ble achievement in overcoming infec-
tious disease during the Nobel era was 
the eradication of smallpox in 1977 by 
the WHO team led by Donald Hender-
son; it cannot qualify for a Nobel Prize in 
Medicine because it was not a discovery, 
so a Peace Prize would be apt.ecember 12, 2008 ©2008 Elsevier Inc. 985
Figure 2. HPV and HIV Bring Home the Prize
Shown are this year’s winners of the Nobel Prize for Physiology or Medicine: (left) Harald zur Hausen of 
the University of Heidelberg and (right) Francoise Barré-Sinoussi and Luc Montagnier of the Pasteur In-
stitute. (Left image courtesy of the German Cancer Research Center; right image courtesy and copyright 
of Institut Pasteur.)Centenary and Silver Anniversary
One hundred years ago, the Nobel 
Prize in Physiology or Medicine was 
awarded to two investigators “in rec-
ognition of their work on immunity” 
who, like this year’s winners, worked 
in France and in Germany. At the Pas-
teur Institute, the Russian scientist Ilya 
Mechnikov discovered phagocytosis, 
while in Berlin and later Frankfurt, Paul 
Ehrlich delineated humoral and cell-
mediated immunity as well as develop-
ing chemotherapy, histopathological 
dyes still in use today, and quantitative 
methods of biological standardization. 
It is also the centenary of the demon-
stration by V. Ellerman and O. Bang in 
Denmark that a filterable agent could 
cause leukemia in chickens (that is, the 
first tumor virus).
The year 1983 was truly a vintage 
one for pathogen discovery. We have 
already savored the Freiburg Riesling 
of HPV and the Pinot Noir Arbois of HIV 
from Louis Pasteur’s own vineyard. It is 
worth recalling that there was a third 
discovery, a Swan Valley Shiraz from 
Western Australia called Helicobacter 
pylori, for which Barry Marshall and 
Robin Warren shared the Nobel Prize in 
2005. Again, the discovery of H. pylori 
and its association with peptic and duo-
denal ulcers, stomach cancer, and later 
mucosal-associated B cell tumors went 986 Cell 135, December 12, 2008 ©2008 Elseagainst prevailing concepts. There was 
no strong epidemiological evidence to 
suggest that these diseases had an 
infectious etiology. Marshall applied 
Koch’s postulates to himself: he swal-
lowed a pure culture of bacteria and 
developed severe dyspepsia. It took 
over a decade for Warren and Mar-
shall to convince physicians (let alone 
pharmaceutical companies) that inex-
pensive antibiotics, which eliminate 
the underlying cause of disease, were 
more effective than the sophisticated 
H2-receptor antagonists, which help to 
control the symptoms.
Conclusion
Discovery is a multistep process in 
which, as Isaac Newton said, those who 
see further have stood on the shoul-
ders of giants. It is the really big steps 
and paradigm shifts that the Nobel 
Committee rewards. Barré-Sinoussi, 
Montagnier, and zur Hausen (Figure 
2) have waited 25 years for their fine 
wines to mature, rather shorter than 
Peyton Rous’s 55 years following his 
1911 discovery of Rous sarcoma virus. 
For me, it has been a privilege to toil 
in the same vineyards of viral oncology 
and HIV/AIDS, while witnessing these 
sparkling discoveries. I warmly toast 
the Laureates of this year’s Nobel Prize 
in Physiology or Medicine.vier Inc.AcknOwleDgmentS
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